Overview Study of Debio 1450 for Bacterial Skin Infections Status: Completed Trial end date: 2016-09-01 Target enrollment: Participant gender: Summary The primary objective of this study is to evaluate the efficacy of 2 different doses of intravenous and oral Debio 1450 compared with intravenous vancomycin and oral linezolid in the treatment of patients with staphylococcal ABSSSI. Phase: Phase 2 Details Lead Sponsor: Debiopharm International SATreatments: LinezolidVancomycin